A therosclerosis is characterized by chronic inflammation of the arterial wall, most notably by infiltration of macrophages (MΦ), accumulation of oxidized low-density lipoproteins, and ultimately conversion of MΦ to foam cells. 1 In physiological states, the macrophages entering the intima either undergo apoptosis, migrate to lymphatic vessels, or exit in the bloodstream, whereas in atherosclerosis, there is net accumulation of macrophages. 2,3 The amount of MΦ in the plaque is clinically important because it is related to unstable vulnerable plaques. 4 The MΦ are further divided into 2 subtypes: classical activation of macrophages results in proinflammatory and proatherogenic phenotype (M1), 5 whereas alternative activation results in phenotype related with tissue repair and anti-inflammatory properties (M2). 6 Accumulation of foam cells leads to augmentation of the inflammatory response, remodeling of the plaque, and activation of smooth muscle cells (SMCs). Means to control MΦ trafficking, SMC activation, and the stability of the plaque may provide novel insights into development of pharmacological strategies to prevent the development of atherosclerosis. 7
exerts its effects by binding to chemoattractive NTN1 receptor deleted in colorectal carcinoma (DCC)/neogenin or chemorepulsive receptor UNC5B. 9 NTN1 inhibits the migration of neutrophils, lymphocytes, and monocytes via UNC5B. 10 When expressed by epithelial cells, NTN1 attenuates tissue accumulation of leukocytes in models of experimental tissue inflammation, ischemia, and reperfusion in lungs, kidneys, and vessel wall. 11, 12 In human atherosclerosis, the effects of NTN1 are unclear. Emigration of MΦ from the plaque is prevented in vitro by NTN1 secreted by MΦ via UNC5B resulting in increased MΦ accumulation. 8 In mice, targeted deletion of NTN1 in MΦ resulted in decreased atherosclerosis in vivo 8 and promoted emigration of MΦ from plaques in vitro. Interestingly, it was speculated that NTN1 in plaques could also induce recruitment of SMCs into the intima and therefore promote plaque progression. 8 In another study, intravenous delivery of NTN1 to hypercholesterolemic mice using viral vectors increased NTN1 expression, presumably on endothelial cells, and resulted in prevention of MΦ infiltration of the nascent plaque. 13 Recent studies have shown that coronary endothelial cells express NTN1, which inhibits migration of human monocytes in vitro. 14 Therefore, NTN1 may either retain the MΦ in the plaque when expressed in the vessel wall by MΦ and SMCs or prevent infiltration of the plaque when expressed in the endothelium. Although recently NTN1 and UNC5B protein have been demonstrated in human atherosclerotic plaques, 15 their association with plaque type and different arterial bed in vivo is lacking.
Present data on the role of NTN1 and its receptors as modulators of MΦ trafficking and SMC activation in atherosclerosis are mostly based on animal and in vitro experiments. We hypothesized that dysregulation of expression of NTN1 and its receptors associate with atherosclerosis and plaque stability in vivo. Using recently published macrophage and SMC signatures, 16 we studied the expression of NTN1 and its receptors in circulating monocytes and human(s) atherosclerotic plaque samples in vivo and their potential association with plaque stability.
Methods

Vascular Samples
Vascular sample series from Tampere Vascular Study (TVS), [17] [18] [19] [20] [21] including femoral arteries, carotid arteries, and abdominal aortas, were obtained during open vascular procedures from 2005 to 2009 from patients fulfilling the following inclusion criteria: (1) carotid endarterectomy because of asymptomatic or symptomatic and hemodynamically significant (>70%) carotid stenosis or (2) femoral or (3) aortic endarterectomy with aortoiliac or aortobifemoral bypass because of symptomatic peripheral arterial disease. The left internal thoracic artery (LITA) samples serving as controls were obtained during coronary artery bypass surgery because of symptomatic coronary artery disease (CAD). An exclusion criterion was a patient's denial to participate in the study. Gene expression was analyzed from carotid (n=29), abdominal aortic (n=15), and femoral (n=24) plaques (cases), and as controls, atherosclerosis-free LITAs (n=28) were used. The study has been approved by the Ethics Committee of Tampere Hospital District. All studies were conducted according to the declaration of Helsinki, and the study subjects gave informed consent. The samples were taken from patients subjected to open vascular surgical procedures in the Division of Vascular Surgery and Heart Center, Tampere University Hospital. The vascular samples were classified according to American Heart Association recommendation. 22 The type V and VI atherosclerotic lesions were further histologically classified as stable and unstable according to the presence of fissure, rupture, hemorrhage, and thrombosis.
Whole Blood and Circulating Monocyte Fractions
TVS whole blood and monocyte collections were performed in 2008. The angiographically verified patient samples were preselected from a larger population-based cross-sectional study 23 comprising patients subjected to an exercise test at Tampere University Hospital and thereafter treated according to the Finnish Current Care Guidelines. RNA was isolated from the whole blood and monocytes of individuals with angiographically verified CAD (n=55) and without coronary artery lesions (n=45). The study began in the beginning of October 2001 with the goal of enrolling ≤5000 patients. Data on the patients included were collected between October 2001 and the end of December 2004. Patient history data are based on hospital records and patient interviews. These data cover demographics, for example, age, sex, weight, etc, and lifestyle information, including alcohol consumption and physical exercise. Classical cardiovascular risk factors and symptoms are also extensively covered. The study also has access to the laboratory tests performed on the patients at Tampere University Hospital between October 1998 and the end of the study.
RNA Isolation and Microarrays
The fresh arterial tissue samples were soaked in RNALater solution (Ambion Inc, Austin, TX) and isolated with Trizol reagent (Invitrogen, Carlsbad, CA) and the RNAEasy Kit with DNase Set (Qiagen, Valencia, CA). From the whole blood fraction, the RNA was isolated with PAXgene tubes (BD, Franklin Lakes, NJ) and PAXgene Blood RNA Kit (Qiagen) with DNase Set. Peripheral mononuclear cells were isolated from the whole blood samples by Ficoll-Paque densitygradient centrifugation (Amersham Pharmacia Biotech UK Limited, Buckinghamshire, England). Total RNA was then extracted using RNeasy Mini Kit (Qiagen). Manufacturers' instructions were followed in all isolation protocols. The quality of the RNA samples was evaluated spectrophotometrically, and the samples were stored in -80°C.
The expression levels of arterial and whole blood samples were analyzed with Illumina HumanHT-12 v3 Expression BeadChip (Illumina, San Diego, CA) analyzing 47 000 transcripts of all known genes, gene candidates, and splice variants. The microarray experiments for the monocyte RNA were performed using Sentrix Human-6 Expression BeadChips analyzing >46 000 transcripts (Illumina). Both arrays were run according to given instructions by the manufacturer and scanned with the Illumina iScan system. More detailed descriptions of the methodology and quantitative reverse transcription polymerase chain reaction validation of the microarrays can be found in notes 24 and 25.
Microarray Data Analysis
After background subtraction, raw intensity data were exported using the Illumina GenomeStudio software. Raw expression data were imported into R (http://www.r-project.org/), log2 transformed and normalized by the locally estimated scatterplot smoothing normalization method implemented in the R/Bioconductor package Lumi (www. bioconductor.org). Locally estimated scatterplot smoothing normalization was selected for the data from all 3 tissues because it gave the best accuracy in comparison with quantitative reverse transcription polymerase chain reaction data for artery samples 24 (data not shown). Data quality control criteria included detection of outlier arrays based on the low number of robustly expressed genes and hierarchical clustering. Artery samples (n=92: 68 plaque, 24 LITA), peripheral blood samples (n=96: 52 CAD, 44 controls), and monocyte samples (n=98: 52 CAD, 46 controls) fulfilled all data quality control criteria. The 68 atherosclerotic plaque samples included tissue from 29 cases with carotid artery, 15 cases with abdominal aorta, and 24 cases with femoral artery. Probes were considered robustly expressed if the detection was P<0.05 for at least half of the samples in the data set. Of the 6 netrin receptors, neogenin-1 (NEO1), UNC5B, and UNC5C were found to be significantly expressed in human atherosclerotic plaques at measurable levels (Tables 1 and 2) . Therefore, these genes were selected for differential expression and correlation analyses. 16 were used in the hierarchical clustering analysis to assess whether subgroups of samples had similar marker profiles as well as whether NTN1 and UNC5B showed similar expression levels across the samples. The procedure was performed using the heatmap.2 function from the gplots R library using all 92 artery samples. Pearson dissimilarity and average linkage were used for the hierarchical clustering of both genes and samples. To further investigate whether NTN1 and NEO1 are measures of plaque cell composition, correlation analyses were performed using previously established macrophage/plaque signatures. 16 
Hierarchical Clustering and Correlation Analyses
NTN1, UNC5B, well-characterized biomarkers of inflammation (chemokine (C-C motif) ligand 2 [CCL2],
Confocal Immunofluorescence Study
For immunofluorescence labeling, vascular samples from femoral arteries, carotid arteries, and LITAs from 3 different patients were fixed in paraformaldehyde, transferred to 30% sucrose buffer and embedded (optimal cutting temperature [O.C.T.], Tissue Tek II, Laboratory Tek Products), frozen in liquid nitrogen, and then stored at −80°C until use. NTN1 was detected with rabbit polyclonal antihuman NTN1 antibody, clone H-104 (Santa-Cruz Biotechnology, Santa Cruz, CA).
The following primary antibodies were used to detect vascular cell markers in adjacent sections: CD68 (mouse antihuman CD68, clone PG-M1, DakoCytomation, Glostrup, Denmark) was used as a marker of monocytes and macrophages and HHF35 as a marker for muscle actin (mouse antihuman muscle actin, clone HHF35, DakoCytomation). All antibodies were diluted in PBS containing 1% BSA and 0.3% of Triton X-100. Frozen sections (7 µm) were cut with Microm HM 560 (Thermo Scientific, Waltham, MA) and thaw-mounted onto Superfrost Plus (Menzel-Gläser, Braunschweig, Germany). After that, glass slides were let to stay 2 hours inside the cryotome. The sections were incubated overnight with the mixture of NTN1 (diluted 1:20) antibody and CD68 (diluted 1:10) or HHF35 (diluted 1:10) followed by a mixture of fluorescein-conjugated sheep anti-mouse antibody (1:10, Amersham Biosciences, Freiburg, Germany) and DyLight549conjugated goat anti-rabbit antibody (1:100, AbD Serotec, Kidlington, UK) for 30 minutes at 37°C. Sections were mounted in a mixture of glycerol and PBS (3:1) containing 0.1% paraphenylenediamine. The immunolabeled sections were examined under a confocal spinning disk microscope (Wallac-Perkin Elmer Ultraview) attached to a Nikon Eclipse Ti microscope. Images were acquired using double laser excitation at 488 nm (fluorescein) and 561 nm (rhodamine) and recorded with Andor EMCCD camera (Andor Technology, Belfast, Northern Ireland). Serial plane images were collected throughout the whole thickness of the fluorescent preparation. Two-dimensional images were obtained by projection of serial tomographs. For comparative analysis, all sections were scanned at the same magnification and confocal laser microscope settings.
Statistical Analyses
Statistical analyses were performed using R version 2.15.0 (http:// www.r-project.org/). To estimate fold changes between groups, we calculated differences between medians (in log2 scale) and then back transformed the log ratios to fold changes. To ease the interpretation, we replaced fold-change values that are <1 by the negative of its inverse. Statistical significance of differences in gene expression was assessed using the nonparametric Wilcoxon signed-rank test and the log-transformed data. For associations between NTN1 levels and SMC/macrophage markers, the Spearman correlation coefficient was used. To test the effect of covariates on expression levels of NTN1, UNC5B, and NEO1, Wilcoxon rank-sum test and Spearman correlation were used. The associations between covariates and expression levels were tested in the atherosclerotic plaque and LITA samples separately and were considered significant when P<0.05/42 to 0.001 according to the Bonferroni correction for multiple testing. Differences were considered significant when P<0.05.
Results
Characteristics of the Subjects and Studied Vascular, Whole Blood, and Monocyte Samples
The description of the study population is presented in Table 3 . Of the atherosclerotic arteries, 74.6% were classified as type V and VI advanced plaques. All the internal mammary arteries that were used as controls were microscopically verified normal. The frequency of body mass index, hypercholesterolemia, hypertension, and myocardial infarction was different between arterial plaques and controls, whereas frequency of hypercholesterolemia, statin usage, CAD, and myocardial infarction was different between monocyte cases and controls (Table 3) . Therefore, the effect of these covariates on gene expression was subsequently analyzed.
Expression of NTN1 and Its Receptors in the Circulating Monocytes and Whole Blood Are Not Altered in Coronary Atherosclerosis
The expression of NTN1 or its receptors (DCC, NEO1, UNC5A, UNC5B, UNC5C, UNC5CL, UNC5D) did not differ in either whole blood or blood circulating monocytes from patients with CAD compared with histologically normal controls (P>0.05 for all). Hypercholesterolemia, statin usage, CAD, or myocardial infarction (Table 2) were not related to NTN1, UNC5B, NEO1 mRNA levels in either the monocytes or blood samples (always P>0.05).
Association of NTN1 and Its Chemorepulsive Receptor UNC5B With Atherosclerotic Plaques and Stability
NTN1 was downregulated and the chemorepulsive receptor UNC5B upregulated in atherosclerotic plaques compared with histologically normal controls (NTN1: −2.7-fold, P<0.0001; UNC5B 1.8-fold; P<0.0001; Figure 1A ). Other robustly expressed NTN1 receptors showed no differences (neogenin ie, NEO1, UNC5C). Stary class (III versus IV and VI) was not associated with either NTN1 or UNC5B expression (P>0.313 for all). NTN1 expression did not differ between thrombosed and nonthrombosed advanced plaques, and there was a trend of decreased expression in unstable advanced plaques compared with stable advanced plaques (P=0.096). Increased levels of UNC5B are associated with increasing histological stability of the type V and VI plaques (P=0.011), and especially those with evidence of hemorrhagia, its expression was decreased in unstable compared with stable plaques ( Figure 1A) . Age, sex, body mass index, hypercholesterolemia, hypertension, statin usage, and myocardial infarction ( Table 3) were not associated with NTN1, UNC5B, or NEO1 expression in either the plaque or the LITA samples after correcting for multiple testing (always P>0.03).
Hierarchical Clustering Analysis: The Association of NTN1 With SMC and of UNC5b With MΦ Markers
Hierarchical clustering based on the expression of the 8 inflammation and SMC marker genes 16 showed distinct separation of plaque samples from controls ( Figure 1B ). Furthermore, the plaque samples from the 3 arterial beds coalesced in 2 branches of the dendrogram. This clustering was dependent on the expression of the SMC markers but independent of the artery bed ( Figure 1B) , the Stary class, or plaque stability (data not shown). In contrast, UNC5B showed similar expression profile across samples with inflammatory markers including MΦ marker CD68 ( Figure 1B ).
NTN1 and NEO1 Expression Levels Are Correlated With SMC, M1, and M2 Signatures in the Atherosclerotic Plaque
Using previously published markers of M1 and M2 macrophage and SMC signature, 16 it was found that NTN1 and NEO1 correlated strongly negatively with macrophage-specific signature and positively with SMC signature (Figure 2 ). Interestingly, a strong negative correlation was found between NTN1 and M2 macrophage signature. There was no clear pattern of correlations for UNC5B with macrophage markers in the plaque ( Figure 2C ).
NTN1 Expression in the Atherosclerotic Plaque Cells According to Confocal Immunofluorescence Analysis
Confocal immunofluorescence analysis showed that NTN1 was colocalized with CD68 indicative of cells of monocytic origin in the atherosclerotic plaques. Only a few inflammatory cells were detected in LITA controls, those showing low NTN1 expression ( Figure 3 ). In addition, NTN1 colocalized with HHF35, indicative of SMCs in the atherosclerotic plaques ( Figure 3 ). The staining in SMCs was of high intensity in the plaque and of medium intensity in the LITA controls. NTN1 was highly expressed in the luminal surface corresponding with the intimal layer of the LITA controls (Figure 4 ).
Discussion
In the present study, we showed that the expression of neuroimmune guidance cue NTN1 was downregulated, and the expression of its chemorepulsive receptor UNC5B was upregulated in atherosclerotic plaques (carotid, femoral, and aortic plaques), whereas no alterations were found in circulating monocytes or whole blood, indicating that this phenomenon is localized in the vessel wall. Interestingly, increased expression of UNC5B showed association with increased plaque stability. NTN1 clustered with SMC markers or cell type, whereas UNC5B clustered with MΦ markers or cell type. NTN1 protein colocalized with both cells of monocytic origin and cells of SMC type in the plaques and only with SMCs in the control samples. NTN1 protein was highly expressed in the intimal layer of the histologically normal control vessels.
Our results in vivo are in line with previous findings demonstrating that NTN1 and UNC5B are expressed in human atherosclerotic plaques in vitro 8 and also in vivo. 15 Recently, it was shown that coronary endothelial cells normally express NTN1, which potently inhibits migration of monocytes in vitro. 26 Our results of downregulation of NTN1 in advanced plaques are supported by the finding that proatherogenic factors (oscillatory shear stress, proinflammatory cytokines) downregulate NTN1 expression in vitro. 14 UNC5B expression differed significantly in unstable plaques compared with histologically more stable plaques. The mechanisms behind regulation of NTN1 and UNC5B expression are complex. There is hypoxia in atherosclerotic plaques, 27 which can activate hypoxia-inducible factor hypoxia-inducible factor 1-α and nuclear factor-κB resulting in alterations in NTN1 expression. 11, 12, 28 Interestingly, oxidized low-density lipoprotein is capable of inducing NTN1 expression via activation of nuclear factor-κB. [29] [30] [31] Recently, the molecular mechanism linking plaque hypoxia and macrophage infiltration has been demonstrated in mouse and human plaques. 15 It involves hypoxia-inducible factor 1α-mediated upregulation of NTN1 and UNC5b in human and mouse atherosclerotic plaques and subsequent macrophage chemostasis and protection from apoptosis. 15 Upregulation of UNC5B expression by hypoxia-inducible factor 1α activation because of plaque hypoxia has been shown in mouse and human atherosclerotic plaques. 15 Taken together, our results suggest that UNC5B associates with the development of unstable plaques presumably because of plaque hypoxia. Upregulation of UNC5B alone may mediate short-range repulsion 9,32 that might render stable plaques resistant to macrophage infiltration, whereas decreased expression would allow macrophage accumulation. In quiescent adult arteries, UNC5B is downregulated, but its expression is upregulated during sprouting angiogenesis. 33 Unstable plaques are characterized with angiogenesis and ultimately plaque hemorrhagia. 7 As binding of NTN1 to UNC5B results in inhibition of sprouting angiogenesis and it has been identified previously as a potential antiangiogenic target, 33 its expression in stable plaques might protect from evolution of the plaque to an unstable one.
Our finding of high intimal expression of NTN1 in histologically normal control vessels could protect from the infiltration by macrophages and explain the clinical finding that internal thoracic arteries seldom develop atherosclerosis. These vessels were obtained from patients undergoing coronary artery bypass grafting and therefore exposed to the systemic factors present in atherosclerosis. Actually, atherosclerotic changes in the LITA have been described, and slight changes were as common as 63.4% in the distal part of the vessel. 34 Significant changes are extremely rare, found in 3.1% of an autopsy material, and not always related to concomitant CAD. 35 Structural preservation of the LITA was demonstrated in patients with type II diabetes mellitus, 36 supporting the existence of an autoprotective effect and possibly a protective effect on the coronaries to be grafted. 37 The expression of NTN1 or its receptors (DCC/neogenin, UNC5A, UNC5B, UNC5C, UNC5CL, UNC5D) did not differ in either whole blood or blood circulating monocytes from patients with CAD compared with histologically normal controls, which may indicate that the mechanisms leading to altered expression of the components of the netrin system are operative only locally in the atherosclerotic plaque. Strong correlation of NTN1 expression with SMC markers and negative correlation with monocyte markers and signatures might indicate that in advanced human plaques, NTN1 expression might be mainly because of SMCs. In contrast, strong correlation of UNC5b with inflammatory markers, including MΦ marker CD68, might indicate expression by MΦs. Our results are supported by previous findings that showed that in human carotid plaques, NTN1 was upregulated in SMC-rich areas fold change [FC] 1.7 and downregulated (FC −3.5) in plaque areas rich in macrophages. 16 Our finding of strong negative correlation of NTN1 with proatherogenic M1 and anti-inflammatory M2 signatures, especially that of anti-inflammatory M2 type, indicates that NTN1 might be involved in the macrophage subtype polarization and therefore determination of plaque phenotype. However, mechanistic in vitro experiments are needed to study this hypothesis. Although NEO1 expression did not differ between plaques and controls, it was robustly expressed in both plaques and controls, and the correlation profiles with both macrophage and SMC markers were similar to those of NTN1. This is partly explained by the fact that NEO1 is a NTN1 receptor in SMCs. 8 This supports our novel result of NTN1 expression in SMCs in both plaques and arterial wall. Similarly, NEO1 correlation profiles provide support for those presented for NTN1.
As a potential limitation, it must be emphasized that because of ethical limitations, we were not able to obtain any corresponding normal arteries from carotid, aortic, and femoral regions as controls. Obviously, this would allow more accurate analysis between healthy subjects and those with atherosclerosis. Because of systemic nature of atherosclerosis, internal thoracic artery samples from patients subjected to coronary artery bypass grafting may be affected by atherosclerosis and several humoral mediators, although no microscopic evidence of plaques could be demonstrated. The reliability of the gene expression results was confirmed by our previous study. 24 As the patients with atherosclerotic plaques were treated because of peripheral arterial disease commonly associated with polyvascular affision of the vasculature, their demographics and risk factor distribution are strikingly different from coronary bypass patients with control samples and patients with whole blood and monocyte samples with exercise stress test and angiography because of suspicion of CAD.
In conclusion, our results indicate that dysregulation of NTN1 and its chemorepulsive receptor UNC5B is involved in the development of atherosclerosis and unstable plaques. According to our results, NTN1 is expressed principally by plaque SMCs, whereas UNC5b is expressed by MΦs. Whether the observed spatial differences in the expression of NTN1 and UNC5B explain the susceptibility of different vascular beds for the development of atherosclerosis and unstable plaques could be therapeutically modulated remains to be elucidated in future mechanistic experiments.
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